Catalog No.
Product Name
Application
Product Information
Citations
-
E3 ligase ligand-linker conjugate
Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology. -
ligand-linker conjugate
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. -
Lenalidomide-based Cereblon ligand
Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
- Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
-
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - (S,R,S)-AHPC-(C3-?PEG)?2-?C6-?Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-?PEG)?2-?C6-?Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
-
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - (S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
- Thalidomide-O-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
-
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs. -
E3 ligase ligand-linker conjugate
cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERs. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-PEG2-propargyl is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a key component of the E3 ubiquitin ligase complex. This compound incorporates a two-unit PEG linker and a propargyl group, making it suitable for click chemistry applications. Thalidomide-O-PEG2-propargyl can facilitate copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling the conjugation of various azide-containing molecules, and is particularly useful in the development of targeted protein degradation strategies in chemical biology research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG1-COOH serves as an E3 ligase ligand-linker conjugate, integrating a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. It is suitable for research applications aimed at investigating protein regulation and therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand covalently attached to a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through the PROTAC technology by engaging the E3 ubiquitin ligase cereblon. Its primary applications include research in protein homeostasis, cancer therapeutics, and the development of new drug modalities in the field of targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-piperazine-Boc is an E3 ligase ligand-linker conjugate that serves as an intermediate in the synthesis of PROTAC targeting B-cell lymphoma 6 protein (BCL6). This compound plays a significant role in targeted protein degradation, facilitating the selective destruction of BCL6 and aiding in research related to cancer therapeutics. Its application is essential for studies focusing on E3 ligase modulation and PROTAC development in oncology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG2-COOH is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG-based linker suitable for PROTAC applications. This compound features an alkyne moiety, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). It serves as a valuable tool for research in targeted protein degradation and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG2-COOH is an E3 ligase ligand-linker conjugate that features the cereblon ligand derived from thalidomide, combined with a PEG-based linker. This compound is designed to enhance targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology. It serves as a valuable tool for research in cellular biology and therapeutic applications by enabling precise modulation of protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand derived from Thalidomide. This compound is designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation in cellular systems. Its unique structure allows for selective engagement of E3 ligases, providing valuable applications in therapeutic research and drug discovery focused on the modulation of protein levels. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C2-acid is an E3 ligase ligand-linker conjugate that features the Thalidomide-derived cereblon ligand, combined with a suitable linker for applications in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted protein degradation, enabling researchers to manipulate protein levels within cells. Its design supports the development of innovative therapeutic strategies by leveraging the ubiquitin-proteasome system for potential applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-O-CH2-COOH is an E3 ligase ligand-linker conjugate that functions as a selective ligand for the Cereblon (CRBN) protein. Its primary role is to facilitate the recruitment of CRBN, making it a valuable intermediate in the synthesis of PROTAC (Proteolysis Targeting Chimeras) molecules targeting CRBN. This compound is essential for research related to targeted protein degradation and therapeutics aimed at modulating cellular proteins through ubiquitin-proteasome pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from Thalidomide. This compound is designed for use in PROTAC (proteolysis targeting chimeras) technology, facilitating the targeted degradation of specific proteins within cellular systems. Its utility in research includes studying protein turnover and exploring therapeutic strategies for various diseases through targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate utilizing the cereblon ligand derived from thalidomide. This compound plays a critical role in the assembly of PROTAC (proteolysis targeting chimera) technologies, facilitating targeted protein degradation. It is primarily used in pharmacological research to investigate E3 ligase-mediated protein modulation and to develop innovative therapeutic strategies in disease treatment. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that incorporates a cereblon ligand derived from Thalidomide. This compound is primarily utilized in the development of PROTACs (proteolysis targeting chimeras), enabling targeted protein degradation. Its unique structure facilitates the recruitment of cognate E3 ligases, thereby promoting the efficient ubiquitination and subsequent degradation of specific target proteins, making it a valuable tool in chemical biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-COOH is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG4 linker. This compound facilitates the targeted protein degradation through the PROTAC (Proteolysis Targeting Chimera) technology, enhancing the selective modulation of protein levels in cellular environments. It serves as a valuable tool for researchers exploring protein homeostasis, pharmacological modulation, and therapy development in various disease contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG1-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker, designed for applications in PROTAC (proteolysis-targeting chimeras) technology. This reagent facilitates the targeted degradation of specified proteins, providing a valuable tool for researchers studying protein homeostasis and therapeutic intervention. Its unique properties make it suitable for various applications in chemical biology, drug discovery, and targeted protein degradation studies. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted protein degradation. Its application is critical in studying the modulation of protein levels in various biological contexts, providing valuable insights into cellular pathways and disease mechanisms. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate the cereblon ligand derived from Thalidomide, along with a flexible linker suitable for PROTAC technology. This compound facilitates targeted protein degradation by linking specific binders to E3 ligases, enabling the modulation of protein expression in cellular studies. Its applications extend to research in drug discovery and the development of innovative therapeutic strategies involving targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates E3
Thalidomide-O-C6-azide is an E3 ligase ligand-linker conjugate that combines the Thalidomide-based cereblon ligand with a versatile linker utilized in PROTAC technology. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. Thalidomide-O-C6-azide is valuable for applications in targeted protein degradation and chemical biology studies.
